Rigel Pharmaceuticals Stock Performance
| RIGL Stock | USD 26.04 1.00 3.99% |
Rigel Pharmaceuticals holds a performance score of 14 on a scale of zero to a hundred. The company holds a Beta of 2.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rigel Pharmaceuticals will likely underperform. Use Rigel Pharmaceuticals downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Rigel Pharmaceuticals.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Rigel Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Rigel Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.99 | Five Day Return 8.5 | Year To Date Return 78.36 | Ten Year Return 26.41 | All Time Return (95.93) |
Last Split Factor 1:10 | Last Split Date 2024-06-27 |
1 | Acquisition by Schorno Dean L of 10000 shares of Rigel Pharmaceuticals at 24.2 subject to Rule 16b-3 | 09/19/2024 |
2 | Rigel Pharmaceuticals Rating Reiterated by HC Wainwright | 10/25/2024 |
3 | Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition | 11/05/2024 |
4 | Rigel Pharmaceuticals Inc Q3 2024 Earnings Report Preview What To Expect | 11/06/2024 |
5 | Rigel Q3 Earnings Snapshot | 11/07/2024 |
6 | Rigel Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong Sales Growth and ... | 11/08/2024 |
7 | Citi raises Rigel Pharma stock target, buy rating on strong Gavreto sales | 11/11/2024 |
8 | Rigel Pharmaceuticals, Inc. Given Average Rating of Moderate Buy by Analysts | 11/14/2024 |
9 | 5 Relative Price Strength Options Available for Investors | 11/18/2024 |
10 | Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 24.5 M |
Rigel |
Rigel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,345 in Rigel Pharmaceuticals on August 25, 2024 and sell it today you would earn a total of 1,259 from holding Rigel Pharmaceuticals or generate 93.61% return on investment over 90 days. Rigel Pharmaceuticals is currently generating 1.231% in daily expected returns and assumes 6.7814% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Rigel, and 76% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rigel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rigel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rigel Pharmaceuticals, and traders can use it to determine the average amount a Rigel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1815
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RIGL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.78 actual daily | 60 60% of assets are less volatile |
Expected Return
| 1.23 actual daily | 24 76% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Rigel Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rigel Pharmaceuticals by adding it to a well-diversified portfolio.
Rigel Pharmaceuticals Fundamentals Growth
Rigel Stock prices reflect investors' perceptions of the future prospects and financial health of Rigel Pharmaceuticals, and Rigel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rigel Stock performance.
| Return On Equity | -6.99 | ||||
| Return On Asset | 0.0461 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 457.81 M | ||||
| Shares Outstanding | 17.61 M | ||||
| Price To Earning | (5.63) X | ||||
| Price To Book | 31.64 X | ||||
| Price To Sales | 2.91 X | ||||
| Revenue | 116.88 M | ||||
| Gross Profit | 53.72 M | ||||
| EBITDA | (16.98 M) | ||||
| Net Income | (25.09 M) | ||||
| Cash And Equivalents | 81.64 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 60.58 M | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | (0.83) X | ||||
| Cash Flow From Operations | (5.74 M) | ||||
| Earnings Per Share | 0.27 X | ||||
| Market Capitalization | 458.69 M | ||||
| Total Asset | 117.22 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46 M | ||||
| Current Asset | 129.02 M | ||||
| Current Liabilities | 33.8 M | ||||
About Rigel Pharmaceuticals Performance
By examining Rigel Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Rigel Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rigel Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 283.48 | 269.30 | |
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | 0.88 | 0.92 |
Things to note about Rigel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rigel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rigel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rigel Pharmaceuticals is way too risky over 90 days horizon | |
| Rigel Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Rigel Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 116.88 M. Net Loss for the year was (25.09 M) with profit before overhead, payroll, taxes, and interest of 53.72 M. | |
| Rigel Pharmaceuticals currently holds about 81.64 M in cash with (5.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Rigel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3 |
- Analyzing Rigel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rigel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rigel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rigel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rigel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rigel Pharmaceuticals' stock. These opinions can provide insight into Rigel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.